Literature DB >> 32016093

Current status of circulating tumor cell androgen receptor splice variant-7 in metastatic castration-resistant prostate cancer.

Shinichi Sakamoto1.   

Abstract

Entities:  

Year:  2019        PMID: 32016093      PMCID: PMC6976487          DOI: 10.21037/atm.2019.12.137

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  17 in total

1.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Authors:  Howard I Scher; Michael J Morris; Walter M Stadler; Celestia Higano; Ethan Basch; Karim Fizazi; Emmanuel S Antonarakis; Tomasz M Beer; Michael A Carducci; Kim N Chi; Paul G Corn; Johann S de Bono; Robert Dreicer; Daniel J George; Elisabeth I Heath; Maha Hussain; Wm Kevin Kelly; Glenn Liu; Christopher Logothetis; David Nanus; Mark N Stein; Dana E Rathkopf; Susan F Slovin; Charles J Ryan; Oliver Sartor; Eric J Small; Matthew Raymond Smith; Cora N Sternberg; Mary-Ellen Taplin; George Wilding; Peter S Nelson; Lawrence H Schwartz; Susan Halabi; Philip W Kantoff; Andrew J Armstrong
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

2.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Authors:  Silke Gillessen; Gerhardt Attard; Tomasz M Beer; Himisha Beltran; Alberto Bossi; Rob Bristow; Brett Carver; Daniel Castellano; Byung Ha Chung; Noel Clarke; Gedske Daugaard; Ian D Davis; Johann de Bono; Rodolfo Borges Dos Reis; Charles G Drake; Ros Eeles; Eleni Efstathiou; Christopher P Evans; Stefano Fanti; Felix Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Celestia S Higano; Nicolas James; Philip Kantoff; Pirkko-Liisa Kellokumpu-Lehtinen; Raja B Khauli; Gero Kramer; Chris Logothetis; Fernando Maluf; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Vedang Murthy; William Oh; Piet Ost; Anwar R Padhani; Chris Parker; Colin C Pritchard; Mack Roach; Mark A Rubin; Charles Ryan; Fred Saad; Oliver Sartor; Howard Scher; Avishay Sella; Neal Shore; Matthew Smith; Howard Soule; Cora N Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Ian Tannock; Bertrand Tombal; Riccardo Valdagni; Thomas Wiegel; Aurelius Omlin
Journal:  Eur Urol       Date:  2017-06-24       Impact factor: 20.096

3.  Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

Authors:  Matti Annala; Gillian Vandekerkhove; Daniel Khalaf; Sinja Taavitsainen; Kevin Beja; Evan W Warner; Katherine Sunderland; Christian Kollmannsberger; Bernhard J Eigl; Daygen Finch; Conrad D Oja; Joanna Vergidis; Muhammad Zulfiqar; Arun A Azad; Matti Nykter; Martin E Gleave; Alexander W Wyatt; Kim N Chi
Journal:  Cancer Discov       Date:  2018-01-24       Impact factor: 39.397

4.  Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.

Authors:  Anis A Hamid; Kathryn P Gray; Grace Shaw; Laura E MacConaill; Carolyn Evan; Brandon Bernard; Massimo Loda; Niall M Corcoran; Eliezer M Van Allen; Atish D Choudhury; Christopher J Sweeney
Journal:  Eur Urol       Date:  2018-12-12       Impact factor: 20.096

5.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

6.  AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.

Authors:  Marzia Del Re; Stefania Crucitta; Andrea Sbrana; Eleonora Rofi; Federico Paolieri; Giulia Gianfilippo; Luca Galli; Alfredo Falcone; Riccardo Morganti; Camillo Porta; Eleni Efstathiou; Ron van Schaik; Guido Jenster; Romano Danesi
Journal:  BJU Int       Date:  2019-05-04       Impact factor: 5.588

7.  Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.

Authors:  Scott T Tagawa; Emmanuel S Antonarakis; Ada Gjyrezi; Giuseppe Galletti; Seaho Kim; Daniel Worroll; John Stewart; Atef Zaher; Ted P Szatrowski; Karla V Ballman; Katsuhiro Kita; Shinsuke Tasaki; Yang Bai; Luigi Portella; Brian J Kirby; Fred Saad; Mario A Eisenberger; David M Nanus; Paraskevi Giannakakou
Journal:  Clin Cancer Res       Date:  2018-10-09       Impact factor: 12.531

8.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

9.  Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

Authors:  Andrew J Armstrong; Susan Halabi; Jun Luo; David M Nanus; Paraskevi Giannakakou; Russell Z Szmulewitz; Daniel C Danila; Patrick Healy; Monika Anand; Colin J Rothwell; Julia Rasmussen; Blair Thornburg; William R Berry; Rhonda S Wilder; Changxue Lu; Yan Chen; John L Silberstein; Gabor Kemeny; Giuseppe Galletti; Jason A Somarelli; Santosh Gupta; Simon G Gregory; Howard I Scher; Ryan Dittamore; Scott T Tagawa; Emmanuel S Antonarakis; Daniel J George
Journal:  J Clin Oncol       Date:  2019-03-13       Impact factor: 44.544

10.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

Authors:  Howard I Scher; David Lu; Nicole A Schreiber; Jessica Louw; Ryon P Graf; Hebert A Vargas; Ann Johnson; Adam Jendrisak; Richard Bambury; Daniel Danila; Brigit McLaughlin; Justin Wahl; Stephanie B Greene; Glenn Heller; Dena Marrinucci; Martin Fleisher; Ryan Dittamore
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

View more
  1 in total

Review 1.  Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse.

Authors:  Chaithanya Chelakkot; Hobin Yang; Young Kee Shin
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.